Revom

Description

Revom Tablet (Domperidone)

Manufacturer: Deurali Janta Pharmaceuticals Pvt. Ltd. Generic Name: Domperidone Availability: Nepal

Overview: Revom Tablet, containing Domperidone, is a peripheral dopamine-receptor blocker primarily used to improve gastrointestinal motility and manage various related symptoms.

Indications for Use: Revom Tablet is indicated for the treatment of:

• Gastritis
• Nausea and Vomiting
• Gastroparesis (delayed gastric emptying)
• Non-ulcer Dyspepsia (indigestion not caused by ulcers)
• Migraine (for associated nausea and vomiting)
• Lactation (to promote milk production, off-label use in some regions)

Dosage Information:

Adults (Oral):

• Nausea and Vomiting: 10-20 mg every 4-8 hours. Maximum daily dose: 80 mg.
• Non-ulcer Dyspepsia: 10 mg three to four times daily. May be increased to 20 mg three to four times daily. The last dose should be taken at bedtime.
• Migraine: 20 mg every 4 hours. Maximum: 4 doses per 24 hours.

Adults (Rectal):

• Nausea and Vomiting: 60 mg twice daily.

Elderly:

• No dosage adjustment is typically needed.

Hepatic Impairment:

• No dosage adjustment is typically needed.

Children (Oral):

• 0.2 – 0.4 mg/kg every 4 – 8 hours daily.

Children (Rectal):

• Under 12 years and over 15 kg: 30 mg twice daily.
• Over 12 years and over 35 kg: 60 mg twice daily.

Renal Impairment:

• Mild to Moderate: No dosage adjustment needed.
• Severe: Dosing should be reduced to 1-2 times daily with prolonged treatment.

Administration:

• Revom Tablet should be taken on an empty stomach.
• Administer 15-30 minutes before meals.

Contraindications: Revom Tablet is contraindicated in patients with:

• Known hypersensitivity to Domperidone or any of its components.
• Gastrointestinal hemorrhage, obstruction, or perforation.
• Prolactin-releasing pituitary tumors.
• It is not recommended for chronic administration or routine prophylaxis of postoperative nausea and vomiting.

Precautions: Exercise caution when administering Revom Tablet to:

• Patients with pheochromocytoma.
• Children under 2 years of age.
• Elderly patients.
• Patients with renal or hepatic impairment.
• There is a risk of cardiac arrhythmias and hypokalemia, especially if administered intravenously.
• Use with caution during pregnancy and lactation.

Interactions:

• May reduce the effectiveness of bromocriptine (hypoprolactinemic effect).
• The prokinetic effect may be antagonized by opioid analgesics and antimuscarinics.
• Potentially Fatal Interaction: Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) can significantly increase serum domperidone levels, leading to an elevated risk of QT prolongation and serious cardiac arrhythmias.

Adverse Effects: Common side effects of Domperidone include:

• Drowsiness
• Extrapyramidal reactions (involuntary movements)
• Galactorrhea (abnormal milk production)
• Gynecomastia (breast enlargement in males)
• Constipation or diarrhea
• Lassitude (lack of energy)
• Decreased libido
• Skin rash, itch

Potentially Fatal Adverse Effects:

• Convulsions
• Arrhythmias and cardiac arrest
• Dysrhythmias in patients with pre-existing cardiovascular disease or hypokalemia
• Seizures
• Hypertensive crisis in patients with pheochromocytoma

Mechanism of Action: Domperidone acts as a peripheral dopamine-receptor blocker. Its primary actions include:

• Increasing esophageal peristalsis.
• Enhancing gastroduodenal coordination.
• Lowering esophageal sphincter pressure.
• Improving gastric motility and peristalsis, thereby facilitating gastric emptying and decreasing small bowel transit time.

Important Note: This information on Revom Tablet from Farmaco Nepal drug index is provided for general knowledge and is not intended for diagnosis, medical advice, or treatment. It should not be considered a substitute for professional medical judgment or consultation with a healthcare provider